Abstract

Poor expression is the key factor hampering the large-scale application of transgenic animal mammary gland bioreactors. A very different approach would be to evaluate the secretion of recombinant proteins into milk in response to a cleavable signal peptide of highly secreted lactoproteins.We previously reported rabbits harboring mammary gland-specific expression vector containing a fusion cDNA (goat β-lactoglobulin (BLG) signal peptide and recombinant human plasminogen activator (rhPA) coding sequences) expressed rhPA in the milk, but we did not realize the signal peptide contributed to the high rhPA concentration and did not mention it at that time. And the molecular structure and biological characteristics still remain unknown. So, rhPA in the milk was purified and characterized in the present study.rhPA was purified from the milk, and the purity of the recovered product was 98% with no loss of biological activity. Analysis of the N-terminal sequence, C-terminal sequence, and the molecular mass of purified rhPA revealed that they matched the theoretical design requirements. The active systemic anaphylaxis (ASA) reactions of the purified rhPA were negative. Taken together, these results indicated that the goat BLG signal peptide can efficiently mediate rhPA secretion into milk and was accurately cleaved off from rhPA by endogenous rabbit signal peptidase.We have reinforced the importance of a rhPA coding region fused to a cleavable heterologous signal peptide from highly secreted goat BLG to improve recombinant protein expression. It is anticipated that these findings will be widely applied to high-yield production of medically important recombinant proteins.

Highlights

  • The ability to recombinantly express a protein of interest of sufficient quantity and quality is critical to many fields of biological science, including the production of bio-pharmaceuticals

  • Lactoproteins that co-eluted with recombinant human plasminogen activator (rhPA) were separated from rhPA by subsequent cation exchange chromatography

  • Two bands of approximately 14 and 29 kDa were visualized as shown in lane 4 of the SDS-PAGE (Figure 2A), which indicated that the purified rhPA was in a two-chain form

Read more

Summary

Introduction

The ability to recombinantly express a protein of interest of sufficient quantity and quality is critical to many fields of biological science, including the production of bio-pharmaceuticals. Bio-pharmaceuticals represent preventative and therapeutic opportunities for a large number of human disorders. Over 250 recombinant therapeutic proteins have been approved, and many more are currently in clinical trials [1]. Transgenic animal mammary glands are the perfect hosts for producing therapeutic recombinant human proteins because of their capacity to perform proper folding and assembly of complex proteins and human-compatible glycosylation [2,3]. The key factor hindering the large-scale application of transgenic animal mammary gland bioreactors is the expression level of recombinant proteins, it is very. The study and development of innovative methods for the rapid production of recombinant proteins are essential

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call